DRG Market Assessment reports

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…

Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is…

Non-alcoholic steatohepatitis (NASH) is rapidly becoming an important public health issue in the top five European markets (France, Germany, Italy, Spain, UK). High prevalence of this multifaceted…

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet and triplet regimens but…

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven…

Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-…

MARKET OUTLOOK Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colon cancer…

The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including…

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney…

The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen/Novartis’s Aimovig (…